Additional results for 'Sequential design approaches for bioequivalence studies with crossover designs'.

Autor: Montague TH; GlaxoSmithKline, Inc., King of Prussia, PA, USA., Potvin D, Diliberti CE, Hauck WW, Parr AF, Schuirmann DJ
Jazyk: angličtina
Zdroj: Pharmaceutical statistics [Pharm Stat] 2012 Jan-Feb; Vol. 11 (1), pp. 8-13. Date of Electronic Publication: 2011 Feb 10.
DOI: 10.1002/pst.483
Abstrakt: In 2008, this group published a paper on approaches for two-stage crossover bioequivalence (BE) studies that allowed for the reestimation of the second-stage sample size based on the variance estimated from the first-stage results. The sequential methods considered used an assumed GMR of 0.95 as part of the method for determining power and sample size. This note adds results for an assumed GMR = 0.90. Two of the methods recommended for GMR = 0.95 in the earlier paper have some unacceptable increases in Type I error rate when the GMR is changed to 0.90. If a sponsor wants to assume 0.90 for the GMR, Method D is recommended. Copyright © 2011 John Wiley & Sons, Ltd.
(Copyright © 2011 John Wiley & Sons, Ltd.)
Databáze: MEDLINE
Externí odkaz: